The Latest SPAC News and Rumors: February 24, 2022
by Marlena Haddad on 2022-02-24 at 12:25pm

 


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News:  Foxo plans to go public through merger with Delwinds Insurance, Forbes announces 4Q and full-year results, and salary of Heliogen CEO could top Goldman

Life Insurance Epigenetics Startup Foxo Plans to Go Public Via SPAC

Foxo Technologies Inc., whose artificial intelligence and genetics technology is used to underwrite life insurance, is going public through a deal with a blank-check company, according to Bloomberg.

The merger with Delwinds Insurance Acquisition Corp. (NYSE:DWIN) will value the combined company at $369 million.

Delwinds raised $201 million in an initial public offering in 2020.

READ

Forbes Announces Fourth Quarter & Full-Year 2021 Financial Results

Forbes Global Media Holdings, Inc., which is pursuing a business combination with Magnum Opus Acquisition Limited (NYSE: OPA), today announced its financial results for the fourth quarter and full-year 2021.

Throughout the fourth quarter, revenue increased 51 percent year-over-year to $94 million, driven by contributions across Media and Consumer businesses. In particular, the Company’s Consumer business was up 72 percent in the fourth quarter year-over-year.

For 2021, revenue increased 40 percent to $259 million compared to $185 million in the prior year period; this exceeded our prior projections of $225 million by 15 percent.


Solar Startup Heliogen’s CEO Pay Could Top Goldman Sachs

A solar-power startup little known outside of the energy industry gave its chief executive officer a bigger pay package last year than banking giant Goldman Sachs Group Inc. (NYSE:GS) lavished on its own leader. It’s also in excess of what Chevron Corp. (NYSE:CVX) and NextEra Energy Inc. (NYSE:NEE) are paying their top executives this year.

Pasadena, California-based Heliogen Inc. (NYSE:HLGN) provided chief executive officer Bill T. Gross with compensation worth $37 million for 2021, according to a filing last month after it went public with Athena Technology in late December.

Gross’s award, however, comes with a catch: It almost entirely consists of options that vest over four years and will be valueless unless he helps lift the company’s stock price back above $9. The shares closed at $4.07 on Tuesday.

READ

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved